Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34168284

A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Leukemia
Publication date
2022 Jan
First author
Dispenzieri A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Dispenzieri A
      type
      Author
    2. name
      Kastritis E
      type
      Author
    3. name
      Wechalekar AD
      type
      Author
    4. name
      Schönland SO
      type
      Author
    5. name
      Kim K
      type
      Author
    6. name
      Sanchorawala V
      type
      Author
    7. name
      Landau HJ
      type
      Author
    8. name
      Kwok F
      type
      Author
    9. name
      Suzuki K
      type
      Author
    10. name
      Comenzo RL
      type
      Author
    11. name
      Berg D
      type
      Author
    12. name
      Liu G
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Dispenzieri A
      type
      Author
    2. name
      Kastritis E
      type
      Author
    3. name
      Wechalekar AD
      type
      Author
    4. name
      Schönland SO
      type
      Author
    5. name
      Kim K
      type
      Author
    6. name
      Sanchorawala V
      type
      Author
    7. name
      Landau HJ
      type
      Author
    8. name
      Kwok F
      type
      Author
    9. name
      Suzuki K
      type
      Author
    10. name
      Comenzo RL
      type
      Author
    11. name
      Berg D
      type
      Author
    12. name
      Liu G
      type
      Author
    bibliography ids
    1. nci-bib-fd20957f6c218f962f37182e
    book metadata
    content sha256
    9a54f8d9579a37b777e394118a3e617817ceb05779f33e602af142b3e99f5061
    document type
    citation
    dois
    1. 10.1038/s41375-021-01317-y
    electronic publication date
    display
    2021 Jun 24
    precision
    day
    year
    2021
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:34168284
    immutable id
    pubmed:34168284@9a54f8d9579a37b777e394118a3e617817ceb05779f33e602af142b3e99f5061
    journal
    abbreviation
    Leukemia
    issn electronic
    1476-5551
    issn print
    0887-6924
    issue
    1
    name
    Leukemia
    nlm unique id
    8704895
    pages
    225-235
    volume
    36
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      34168284
      provenance
      batch id
      192b6392c165c6b06274
      provider
      NCBI PubMed ESummary
      record sha256
      fa0e4149b41644534d7e990273ffb6be6e7b73fb3ba4e842b947ebc38eeb20e4
      response sha256
      7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
      retrieved at
      2026-09-09T23:48:02.713075+00:00
      publication date
      display
      2022 Jan
      precision
      month
      year
      2022
      publication types
      1. Clinical Trial, Phase III
      2. Comparative Study
      3. Journal Article
      4. Multicenter Study
      5. Randomized Controlled Trial
      6. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/34168284/
      title
      A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.

      Preserved source evidence · Not medical advice